FDA typically brings new product applications to advisory committees to get its external experts' views on the robustness of the clinical efficacy and safety data and ability of the products to fit into clinical practice.
In the case of the early biosimilar advisory committee meetings, however, a different dynamic has been evident, with FDA having to explain the relevance the analytical characterization and clinical data and respond to